A detailed history of Barclays PLC transactions in Greenwich Life Sciences, Inc. stock. As of the latest transaction made, Barclays PLC holds 8,560 shares of GLSI stock, worth $105,116. This represents 0.0% of its overall portfolio holdings.

Number of Shares
8,560
Previous 8,560 -0.0%
Holding current value
$105,116
Previous $123,000 -0.0%
% of portfolio
0.0%
Previous 0.0%

Shares

4 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q3 2024

Nov 15, 2024

BUY
$12.99 - $17.58 $84,928 - $114,938
6,538 Added 323.34%
8,560 $123,000
Q2 2024

Aug 14, 2024

BUY
$12.07 - $19.04 $24,405 - $38,498
2,022 New
2,022 $35,000
Q2 2022

Aug 12, 2022

SELL
$7.14 - $20.36 $4,748 - $13,539
-665 Closed
0 $0
Q1 2022

May 16, 2022

BUY
$16.3 - $24.65 $10,839 - $16,392
665 New
665 $13,000

Others Institutions Holding GLSI

About Greenwich LifeSciences, Inc.


  • Ticker GLSI
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 12,848,200
  • Market Cap $158M
  • Description
  • Greenwich LifeSciences, Inc., a clinical stage biopharmaceutical company, focuses on the development of novel cancer immunotherapies for breast cancer and other HER2/neu-expressing cancers. Its lead product candidate is the GP2, an immunotherapy, which has completed Phase IIb clinical trial to prevent breast cancer recurrences in patients who ha...
More about GLSI
Track This Portfolio

Track Barclays PLC Portfolio

Follow Barclays PLC and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Barclays PLC, based on Form 13F filings with the SEC.

News

Stay updated on Barclays PLC with notifications on news.